Smallpox vaccine safety is dependent on T cells and not B cells
Shari N Gordon, Valentina Cecchinato, Vibeke Andresen, Jean-Michel Heraud, Anna Hryniewicz, Robyn Washington Parks, David Venzon, Hye-kyung Chung, Tatiana Karpova, James McNally, Peter Silvera, Keith A Reimann, Hajime Matsui, Tomomi Kanehara, Yasuhiko Shinmura, Hiroyuki Yokote, Genoveffa Franchini, Shari N Gordon, Valentina Cecchinato, Vibeke Andresen, Jean-Michel Heraud, Anna Hryniewicz, Robyn Washington Parks, David Venzon, Hye-kyung Chung, Tatiana Karpova, James McNally, Peter Silvera, Keith A Reimann, Hajime Matsui, Tomomi Kanehara, Yasuhiko Shinmura, Hiroyuki Yokote, Genoveffa Franchini
Abstract
The licensed smallpox vaccine, ACAM2000, is a cell culture derivative of Dryvax. Both ACAM2000 and Dryvax are administered by skin scarification and can cause progressive vaccinia, with skin lesions that disseminate to distal sites. We have investigated the immunologic basis of the containment of vaccinia in the skin with the goal to identify safer vaccines for smallpox. Macaques were depleted systemically of T or B cells and vaccinated with either Dryvax or an attenuated vaccinia vaccine, LC16m8. B cell depletion did not affect the size of skin lesions induced by either vaccine. However, while depletion of both CD4(+) and CD8(+) T cells had no adverse effects on LC16m8-vaccinated animals, it caused progressive vaccinia in macaques immunized with Dryvax. As both Dryvax and LC16m8 vaccines protect healthy macaques from a lethal monkeypox intravenous challenge, our data identify LC16m8 as a safer and effective alternative to ACAM2000 and Dryvax vaccines for immunocompromised individuals.
Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011.
Figures
References
- Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Geneva: World Health Organization; 1988.
- Henderson DA. The looming threat of bioterrorism. Science. 1999;283:1279–82.
- Bray M, Wright ME. Progressive vaccinia. Clin Infect Dis. 2003;36:766–74.
- Chen RT, Lane JM. Myocarditis: the unexpected return of smallpox vaccine adverse events. Lancet. 2003;362:1345–6.
- Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis. 2003;37:251–71.
- Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med. 969;281:1201–8.
- Bray M. Pathogenesis of potential antiviral therapy of complications of smallpox vaccination. Antivir Res. 2003 In press.
- Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics. 1975;55:342–7.
- Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:673–6.
- Kempe CH. Studies smallpox and complications of smallpox vaccination. Pediatrics. 1960;26:176–89.
- Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis. 2008;46:1555–61.
- Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep. 009;58:532–6.
- Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs. 2008;17:555–64.
- Handley L, Buller RM, Frey SE, Bellone C, Parker S. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev Vaccines. 2009;8:841–50.
- Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther. 2010;4:71–9.
- Frey SE, Newman FK, Kennedy JS, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 2009;27:1637–44.
- Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine. 2008;26:581–8.
- Beachkofsky TM, Carrizales SC, Bidinger JJ, Hrncir DE, Whittemore DE, Hivnor CM. Adverse events following smallpox vaccination with ACAM2000 in a military population. Arch Dermatol. 2010;146:656–61.
- Artenstein AW, Johnson C, Marbury TC, et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine. 2005;23:3301–9.
- Slifka MK. The Future of smallpox vaccination: is MVA the key? Med Immunol. 2005;4:2.
- Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine. 2006;24:7009–22.
- Hashizume S, Yoshizawa H, Morita M, Suzuki K. Proceedings of the Workshop on vaccinia Viruses as Vectors for vaccine Antigens. 1984. pp. 87–8.
- Morikawa S, Sakiyama T, Hasegawa H, et al. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J Virol. 2005;79:11873–91.
- Saijo M, Ami Y, Suzaki Y, et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol. 2006;80:5179–88.
- Empig C, Kenner JR, Perret-Gentil M, et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine. 2006;24:3686–94.
- Saito T, Fujii T, Kanatani Y, et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA. 2009;301:1025–33.
- Meseda CA, Mayer AE, Kumar A, et al. Comparative evaluation of the immune response and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin Vaccine Immunol. 2009
- Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis) Lab Invest. 2001;81:1581–600.
- Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005;11:740–7.
- Gordon SN, Weissman AR, Cecchinato V, et al. Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques. J Virol. 2010;84:3043–58.
- Schmitz JE, Simon MA, Kuroda MJ, et al. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol. 1999;154:1923–32.
- Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19–28.
- Engram JC, Cervasi B, Borghans JA, et al. Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates. Blood. 2010;116:748–58.
- Edghill-Smith Y, Venzon D, Karpova T, et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis. 2003;188:1181–91.
- Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep. 001;50(RR-10):1–25.
- Vaccari M, Mattapallil J, Song K, et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol. 2008;82:9629–38.
- Karem KL, Reynolds M, Hughes C, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol. 2007;14:1318–27.
- Aragon TJ, Ulrich S, Fernyak S, Rutherford GW. Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968. MC Public Health. 2003;3:26.
- Kidokoro M, Tashiro M, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A. 2005;102:4152–7.
- Freyschmidt EJ, Mathias CB, Diaz N, et al. Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. J Immunol. 2010;185:1295–302.
- Kawakami Y, Tomimori Y, Yumoto K, et al. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med. 2009;206:1219–25.
- Jensen JR, Sand TT, Jorgensen AS, Thestrup-Pedersen K. Modulation of natural killer cell activity in patients with atopic dermatitis. J Invest Dermatol. 1984;82:30–4.
- Lever RS, Lesko MJ, Mackie RM, Parrott DM. Natural-killer-cell activity in atopic dermatitis. Clin Allergy. 1984;14:483–90.
- Verhagen J, Akdis M, Traidl-Hoffmann C, et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol. 2006;117:176–83.
- Orihara K, Narita M, Tobe T, et al. Circulating Foxp3+CD4+ cell numbers in atopic patients and healthy control subjects. J Allergy Clin Immunol. 2007;120:960–2.
- Torreilles SL, Luong RH, Felt SA, McClure DE. Tacrolimus ointment: a novel and effective topical treatment of localized atopic dermatitis in a rhesus macaque (Macaca mulatta) J Am Assoc Lab Anim Sci. 2009;48:307–11.
Source: PubMed